Indivior Pharmaceuticals (INDV) Share-based Compensation (2024 - 2026)

Indivior Pharmaceuticals' Share-based Compensation history runs 3 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 50.0% year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $29.0 million (up 20.83% YoY), while the FY2025 annual figure was $26.0 million, up 8.33% from the prior year.
• Share-based Compensation was $9.0 million for Q1 2026 at Indivior Pharmaceuticals, up from $5.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $9.0 million in Q1 2026 to a low of $5.0 million in Q4 2025.
• Historically, Share-based Compensation has averaged $6.6 million across 3 years, with a median of $6.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation slipped 16.67% in 2025, then jumped 50.0% in 2026.
• A 3-year view of Share-based Compensation shows it stood at $6.0 million in 2024, then retreated by 16.67% to $5.0 million in 2025, then jumped by 80.0% to $9.0 million in 2026.
• The last three Share-based Compensation figures came in at $9.0 million (Q1 2026), $5.0 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.